NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Final decision from the European Commission is anticipated within the coming months
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Investment is additive to KKR’s existing health care growth strategy
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Subscribe To Our Newsletter & Stay Updated
